- Home
- MOLN vs INZY Comparison
MOLN vs INZY Comparison
Compare MOLN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- INZY
- Stock Information
- Founded
- MOLN 2004
- INZY 2015
- Country
- MOLN Switzerland
- INZY United States
- Employees
- MOLN N/A
- INZY N/A
- Industry
- MOLN
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- INZY Health Care
- Exchange
- MOLN Nasdaq
- INZY Nasdaq
- Market Cap
- MOLN 195.4M
- INZY 188.2M
- IPO Year
- MOLN 2021
- INZY 2020
- Fundamental
- Price
- MOLN $5.33
- INZY $1.41
- Analyst Decision
- MOLN
- INZY Strong Buy
- Analyst Count
- MOLN 0
- INZY 8
- Target Price
- MOLN N/A
- INZY $17.75
- AVG Volume (30 Days)
- MOLN 6.0K
- INZY 889.1K
- Earning Date
- MOLN 03-13-2025
- INZY 03-11-2025
- Dividend Yield
- MOLN N/A
- INZY N/A
- EPS Growth
- MOLN N/A
- INZY N/A
- EPS
- MOLN N/A
- INZY N/A
- Revenue
- MOLN $7,105,397.00
- INZY N/A
- Revenue This Year
- MOLN N/A
- INZY N/A
- Revenue Next Year
- MOLN $29.41
- INZY N/A
- P/E Ratio
- MOLN N/A
- INZY N/A
- Revenue Growth
- MOLN N/A
- INZY N/A
- 52 Week Low
- MOLN $3.32
- INZY $1.24
- 52 Week High
- MOLN $12.70
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- MOLN 49.14
- INZY 24.92
- Support Level
- MOLN $5.25
- INZY $1.24
- Resistance Level
- MOLN $5.33
- INZY $1.44
- Average True Range (ATR)
- MOLN 0.20
- INZY 0.25
- MACD
- MOLN 0.02
- INZY -0.07
- Stochastic Oscillator
- MOLN 44.23
- INZY 9.00
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.